nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2011 | Original Article

Post-treatment [¹⁸F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma

verfasst von: Hyun Hoon Chung, Jae Weon Kim, Keon Wook Kang, Noh-Hyun Park, Yong-Sang Song, June-Key Chung, Soon-Beom Kang

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study was to determine whether post-treatment [¹⁸F]fluorodeoxyglucose (FDG) uptake measured as the maximum standardized uptake value (SUV_max) by integrated positron emission tomography (PET)/computed tomography (CT) imaging has prognostic significance in patients with endometrial carcinoma.

Methods

Patients previously treated by primary surgical staging for endometrial carcinoma were imaged with integrated FDG PET/CT during surveillance. PET/CT findings were compared with histological or clinical evaluation, and the relationship between SUV_max on PET/CT and recurrence was examined.

Results

A total of 61 patients were eligible for analysis. Medical records were retrospectively reviewed for clinical data, treatment modalities and outcome. The median duration of follow-up was 31 months (range 6–102 months) post-treatment. SUV_max levels were inversely associated with disease-free survival (DFS). Patients were divided into two groups according to SUV_max (<4.25 versus ≥ 4.25). The Kaplan-Meier survival graph showed a significant difference in DFS between groups [p < 0.001, hazard ratio (HR) 12.959, 95% confidence interval (CI) 3.650–46.011]. In multivariate analyses, post-treatment SUV_max (uncategorized values) evaluated by surveillance PET/CT (p = 0.001, HR 1.199, 95% CI 1.077–1.334) and serous adenocarcinoma histology (p = 0.028, HR 5.594, 95% CI 1.207–25.931) were significantly associated with recurrence.

Conclusion

Post-treatment FDG uptake as measured by SUV_max showed a significant association with recurrence in patients with endometrial carcinoma and may be used as a new useful prognostic marker.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.CrossRefPubMed

Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035–41.CrossRefPubMed

Podczaski E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol 1992;47:323–7.CrossRefPubMed

Carey MS, O’Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995;57:138–44. doi:10.1006/gyno.1995.1115S0090-8258(85)71115-8.CrossRefPubMed

Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55–65.CrossRefPubMed

Ayhan A, Tuncer R, Tuncer ZS, Yüce K, Küçükali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases). Int J Gynecol Cancer 1994;4:306–9. doi:10.1046/j.1525-1438.1994.04050306.x.CrossRefPubMed

Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640–9.CrossRefPubMed

Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 1998;69:192–6. doi:10.1006/gyno.1998.5018S0090-8258(98)95018-1.CrossRefPubMed

Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305–32. doi:10.1148/radiol.23120211852312021185.CrossRefPubMed

10.

Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135–41.PubMed

11.

Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95.PubMed

12.

Chung HH, Kim SK, Kim TH, Lee S, Kang KW, Kim JY, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006;103:165–70. doi:10.1016/j.ygyno.2006.02.016S0090-8258(06)00178-8.CrossRefPubMed

13.

Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529–34. doi:10.1016/j.ygyno.2006.09.009S0090-8258(06)00716-5.CrossRefPubMed

14.

Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1132–9. doi:10.1007/s00259-002-0878-2.CrossRefPubMed

15.

Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:347–52.PubMed

16.

Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167–71. doi:10.1200/JCO.2004.09.035.CrossRefPubMed

17.

Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000;25:905–10.CrossRefPubMed

18.

Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA, et al. Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 2000;3:223–30.CrossRefPubMed

19.

Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85:53–8.CrossRefPubMed

20.

Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34:480–6. doi:10.1007/s00259-006-0260-x.CrossRefPubMed

21.

Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, et al. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008;35:1081–8. doi:10.1007/s00259-007-0687-8.CrossRefPubMed

22.

Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546–51. doi:10.1016/j.ygyno.2004.08.009S0090-8258(04)00627-423.CrossRefPubMed

23.

Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007;17:890–6. doi:10.1111/j.1525-1438.2007.00859.x.CrossRefPubMed

24.

Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. Int J Gynecol Cancer 2010;20:110–5. doi: 10.1111/IGC.0b013e3181c3a28800009577-201001000-00018.CrossRefPubMed

25.

Saga T, Higashi T, Ishimori T, Mamede M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003;17:197–203.CrossRefPubMed

26.

Chao A, Chang TC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:36–44. doi:10.1007/s00259-005-1876-y.CrossRefPubMed

27.

Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36:362–72. doi:10.1007/s00259-008-0956-1.CrossRefPubMed

28.

Horiuchi C, Tsukuda M, Taguchi T, Ishiguro Y, Okudera K, Inoue T. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med 2008;22:693–8. doi:10.1007/s12149-008-0162-z.CrossRefPubMed

29.

Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771–5. doi:10.2967/jnumed.106.037291.CrossRefPubMed

30.

Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004;45:22–9.PubMed

31.

Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47. doi:10.1038/nrc704.CrossRefPubMed

Titel: Post-treatment [18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma
verfasst von: Hyun Hoon Chung
Jae Weon Kim
Keon Wook Kang
Noh-Hyun Park
Yong-Sang Song
June-Key Chung
Soon-Beom Kang
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2011
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1614-y

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Oops ... we did it again!

Book review: S. Mirzaei and M. Schenk (eds) Abbilder der Folter

18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging

The flare phenomenon: still learning after 35 years

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

The role of 18F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients’ treatment decision making?